Literature DB >> 27871039

Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins.

Di-Zao Li1, Qiang-Zhe Zhang2, Cun-Ying Wang3, Yan-Ling Zhang4, Xing-Yu Li2, Ji-Tao Huang2, Hong-Yan Liu5, Zhao-Di Fu5, Hua-Xian Song6, Jin-Ping Lin6, Teng-Fei Ji7, Xian-Dao Pan8.   

Abstract

A series of novel substituted uracil-1'(N)-acetic acid esters (6-20) of camptothecins (CPTs) were synthesized by the acylation method. These new compounds were evaluated for in vitro antitumor activity against tumor cell lines, A549, Bel7402, BGC-823, HCT-8 and A2780. In vitro results showed that most of the derivatives exhibited comparable or superior cytotoxicity compare to CPT (1) and topotecan (TPT, 2), with 12 and 13 possessing the best efficacy. Four compounds, 9, 12, 13 and 16, were selected to be evaluated for in vivo antitumor activity against H22, BGC-823 and Bel-7402 in mice. In vivo testing results indicated that 12 and 13 had antitumor activity against mouse liver carcinoma H22 close to Paclitaxel and cyclophosphamide. 12 had similar antitumor activity against human gastric carcinoma BGC-823 in nude mice compared to irinotecan (3) and possessed better antitumor activity against human hepatocarcinoma Bel-7402 in nude mice than 2. It is also discovered that 12 showed a similar mechanism but better inhibitory activity on topoisomerase I (Topo I) compared to 2. These findings indicate that 20(S)-O-fluorouracil-1'(N)-acetic acid ester derivative of CPTs, 12, could be developed as an antitumor drug candidate for clinical trial. Copyright Â
© 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antitumor activity; Camptothecin; Substituted uracil-1′(N)-acetic acid; Synthesis; The mechanism of antitumor activity

Mesh:

Substances:

Year:  2016        PMID: 27871039     DOI: 10.1016/j.ejmech.2016.11.013

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

Review 1.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  A novel irinotecan derivative ZBH-1207 with different anti-tumor mechanism from CPT-11 against colon cancer cells.

Authors:  Dawei Zhao; Di Wu; Gengyue Zhang; Yongqi Li; Weiguo Shi; Bohua Zhong; Hong Yu
Journal:  Mol Biol Rep       Date:  2022-06-29       Impact factor: 2.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.